Recombinant luteinizing hormone supplementation to recombinant follicle stimulating hormone therapy in gonadotropin releasing hormone analogue cycles: what is the evidence?

References

• Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-8
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Albano C, Ludwig M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015-20
   PubMed Web of Science ®Google Scholar
• Durnerin CI, Erb K, Fleming R, et al.; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008;23:421-6
   PubMed Web of Science ®Google Scholar
• Lisi F, Caserta D, Montanino M, et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in-vitro fertilization in downregulated patients. Gynecol Endocrinol 2012;28:674-7
   PubMed Web of Science ®Google Scholar
• Oliveira JB, Mauri AL, Petersen CG, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis. J Assist Reprod Genet 2007;24:67-75
   PubMed Web of Science ®Google Scholar
• Baruffi RL, Mauri AL, Petersen CG, et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online 2007;14:14-25
   PubMed Web of Science ®Google Scholar
• Kolibianakis E, Kalogeropoulou1 L, Griesinger G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007;13:445-52
   PubMed Web of Science ®Google Scholar
• Mochtar MH, Van der Veen F, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007;97:CD005070
   Google Scholar
• Hill MJ, Levens ED, Levy G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012;97:1108-14
   PubMed Web of Science ®Google Scholar
• Lehert P, Kolibianakis EM, Venetis CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:17
   PubMed Web of Science ®Google Scholar
• Xiong Y, Bu Z, Dai W, et al. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:109
   PubMed Web of Science ®Google Scholar
• Santi D, Casarini L, Carlo Alviggi C, Simoni M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the “personalized” medicine era: a meta-analysis. Front Endocrinol 2017;8:114
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, Gianaroli L, Magli MC, et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521-6
   PubMed Web of Science ®Google Scholar
• De Placido G, Alviggi C, Perino A, et al.; Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005;20:390-6
   PubMed Web of Science ®Google Scholar
• Hill MJ, Levy G, Levens ED. Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reprod Biomed Online 2012;24:261-71
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011;95:1031-6
   PubMed Web of Science ®Google Scholar
• König TE, van der Houwen LE, Overbeek A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013;28:2804-12
   PubMed Web of Science ®Google Scholar
• Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years; a randomized controlled trial. Hum Reprod 2015;30:1188-95
   PubMed Web of Science ®Google Scholar
• Younis JS, Izhaki I, Ben-Ami M. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study. Clin Endocrinol (Oxf) 2016;84:99-106
   PubMed Web of Science ®Google Scholar
• Fischer R. Understanding the role of LH: myths and facts. Reprod Biomed Online 2007;15:468-77
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F. Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol 2002;14:265-74
   PubMed Web of Science ®Google Scholar
• Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77:1170-7
   PubMed Web of Science ®Google Scholar
• Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788-92
   PubMed Web of Science ®Google Scholar
• Westergaard LG, Erb K, Laursen SB, et al. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril 2001;76:543-9
   PubMed Web of Science ®Google Scholar
• Balasch J, Vidal E, Peñarrubia J, et al. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod 2001;16:1636-43
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, Andersen CY. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod 2002;17:2016-21
   PubMed Web of Science ®Google Scholar
• Cabrera RA, Stadtmauer L, Mayer JF, et al. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril 2005;83:42-8
   PubMed Web of Science ®Google Scholar
• Lahoud R, Al-Jefout M, Tyler J, et al. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates. Hum Reprod 2006;21:2645-9
   PubMed Web of Science ®Google Scholar
• Merviel P, Antoine JM, Mathieu E, et al. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril 2004;82:119-25
   PubMed Web of Science ®Google Scholar
• Bosch E, Escudero E, Crespo J, et al. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome. Fertil Steril 2005;84:1529-32
   PubMed Web of Science ®Google Scholar
• Doody KJ, Devroey P, Leader A, et al. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa. Reprod Biomed Online 2011;23:449-56
   PubMed Web of Science ®Google Scholar
• Griesinger G, Shapiro DB, Kolibianakis EM, et al. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. Reprod Biomed Online 2011;23:457-65
   PubMed Web of Science ®Google Scholar
• Huirne JA, van Loenen AC, Schats R, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod 2005;20:359-67
   PubMed Web of Science ®Google Scholar
• Younis JS, Izhaki I, Ben-Ami M. The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age. J Endocrinol Invest 2017;40:831-9
   PubMed Web of Science ®Google Scholar
• Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917-22
   PubMed Web of Science ®Google Scholar
• The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998;13:3023-31
   PubMed Web of Science ®Google Scholar
• Kol S. Individualized treatment from theory to practice: the private case of adding LH during GnRH antagonist-based stimulation protocol. Clin Med Insights Reprod Health 2014;8:59-64
   PubMedGoogle Scholar
• Alviggi C, Pettersson K, Longobardi S, et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol 2013;11:51
   PubMed Web of Science ®Google Scholar
• Lindgren I, Bååth M, Uvebrant K, et al. Combined assessment of polymorphisms in the LHCGR and FSHR genes predict chance of pregnancy after in vitro fertilization. Hum Reprod 2016;31:672-83
   PubMed Web of Science ®Google Scholar
• Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-8
   PubMed Web of Science ®Google Scholar
• Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-12
   PubMed Web of Science ®Google Scholar
• Haavisto AM, Dunkel L, Pettersson K, Huhtaniemi I. LH measurements by in vitro bioassay and a highly sensitive immunofluorometric assay improve the distinction between boys with constitutional delay of puberty and hypogonadotropic hypogonadism. Pediatr Res 1990;27:211-14
   PubMed Web of Science ®Google Scholar
• Shemesh M. Actions of gonadotrophins on the uterus. Reproduction 2001;121:835-42
   PubMed Web of Science ®Google Scholar